Brief: Caladrius Biosciences Treats First Patient In Trial Of CLBS201 For Treatment Of Diabetic Kidney Disease
12/04/2022 13:12
April 12 (Reuters) - Caladrius Biosciences Inc CLBS.O :
* CALADRIUS BIOSCIENCES TREATS FIRST PATIENT IN THE PHASE 1B
TRIAL
OF CLBS201 FOR THE TREATMENT OF DIABETIC KIDNEY DISEASE
Source text for Eikon: ID:nGNXb83xFD
Further company coverage: CLBS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal